NIKKEI 225
38,490.17 -347.29 (-0.89%) HANG SENG
18,424.96 -19.15 (-0.10%) CRUDE OIL
74.42 +0.35 (+0.47%) GOLD FUTURES
2,375.10 -0.40 (-0.02%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,605.23 +484.92 (+0.88%)
JNJ Jun 2025 190.000 call
- Zacks
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.
- Business Wire
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J., June 04, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s execut
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
